Castle Biosciences (CSTL)
Market Price (9/13/2026): $32.29 | Market Cap: $981.6 MilSector: Health Care | Industry: Life Sciences Tools & Services
Castle Biosciences (CSTL)
Market Price (9/13/2026): $32.29Market Cap: $981.6 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -2.0% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.0% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 23x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.1% Key risksCSTL key risks include [1] its demonstrated challenge in achieving profitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -31%, 3Y Excs Rtn is -2.0% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.0% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 23x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.1% |
| Key risksCSTL key risks include [1] its demonstrated challenge in achieving profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/9/2026
Castle Biosciences (CSTL) stock has gained about 55% since 5/31/2026 because of the following key factors:
1. Castle Biosciences (CSTL) significantly exceeded fiscal Q2 2026 earnings expectations and raised its full-year revenue guidance. The company reported fiscal Q2 2026 (ended June 30, 2026) earnings on July 30, 2026, with an adjusted loss per share of -$0.07, substantially better than analysts' consensus estimate of -$0.41. Revenue for the quarter reached $103.5 million, surpassing analyst projections of approximately $86.23 million to $86.4 million. Following these results, management increased its full-year 2026 revenue guidance to a range of $365 million to $375 million, up from the previous range of $345 million to $355 million, representing a $20 million increase at the midpoint. The company also projected achieving positive Adjusted EBITDA for fiscal Q3 2026, Q4 2026, and the full year 2026. This strong financial performance and optimistic outlook contributed to a favorable market response, with the stock closing up 9.32% on the day of the announcement and gaining another 7.28% in after-hours trading.
2. Key diagnostic tests demonstrated robust volume growth and expanded market access through regulatory approvals. The TissueCypher® Barrett's Esophagus test showed significant momentum, with 14,988 test reports delivered in fiscal Q2 2026, marking a 63% year-over-year increase compared to fiscal Q2 2025. Full-year volume for TissueCypher is projected to trend towards 50% to 52% growth. Additionally, the AdvanceAD-Tx™ test, designed to guide systemic treatment for atopic dermatitis, received assay approval from the New York State Department of Health on July 14, 2026, expanding its availability to patients in New York. This test had previously won the "Genomics Innovation Award" on May 12, 2026.
Show more
Castle Biosciences (CSTL) stock has gained about 55% since 5/31/2026 because of the following key factors:
1. Castle Biosciences (CSTL) significantly exceeded fiscal Q2 2026 earnings expectations and raised its full-year revenue guidance. The company reported fiscal Q2 2026 (ended June 30, 2026) earnings on July 30, 2026, with an adjusted loss per share of -$0.07, substantially better than analysts' consensus estimate of -$0.41. Revenue for the quarter reached $103.5 million, surpassing analyst projections of approximately $86.23 million to $86.4 million. Following these results, management increased its full-year 2026 revenue guidance to a range of $365 million to $375 million, up from the previous range of $345 million to $355 million, representing a $20 million increase at the midpoint. The company also projected achieving positive Adjusted EBITDA for fiscal Q3 2026, Q4 2026, and the full year 2026. This strong financial performance and optimistic outlook contributed to a favorable market response, with the stock closing up 9.32% on the day of the announcement and gaining another 7.28% in after-hours trading.
2. Key diagnostic tests demonstrated robust volume growth and expanded market access through regulatory approvals. The TissueCypher® Barrett's Esophagus test showed significant momentum, with 14,988 test reports delivered in fiscal Q2 2026, marking a 63% year-over-year increase compared to fiscal Q2 2025. Full-year volume for TissueCypher is projected to trend towards 50% to 52% growth. Additionally, the AdvanceAD-Tx™ test, designed to guide systemic treatment for atopic dermatitis, received assay approval from the New York State Department of Health on July 14, 2026, expanding its availability to patients in New York. This test had previously won the "Genomics Innovation Award" on May 12, 2026.
Show more
Updated on 9/9/2026
Castle Biosciences (CSTL) stock has gained about 55% since 5/31/2026 because of the following key factors:
1. Castle Biosciences (CSTL) significantly exceeded fiscal Q2 2026 earnings expectations and raised its full-year revenue guidance. The company reported fiscal Q2 2026 (ended June 30, 2026) earnings on July 30, 2026, with an adjusted loss per share of -$0.07, substantially better than analysts' consensus estimate of -$0.41. Revenue for the quarter reached $103.5 million, surpassing analyst projections of approximately $86.23 million to $86.4 million. Following these results, management increased its full-year 2026 revenue guidance to a range of $365 million to $375 million, up from the previous range of $345 million to $355 million, representing a $20 million increase at the midpoint. The company also projected achieving positive Adjusted EBITDA for fiscal Q3 2026, Q4 2026, and the full year 2026. This strong financial performance and optimistic outlook contributed to a favorable market response, with the stock closing up 9.32% on the day of the announcement and gaining another 7.28% in after-hours trading.
2. Key diagnostic tests demonstrated robust volume growth and expanded market access through regulatory approvals. The TissueCypher® Barrett's Esophagus test showed significant momentum, with 14,988 test reports delivered in fiscal Q2 2026, marking a 63% year-over-year increase compared to fiscal Q2 2025. Full-year volume for TissueCypher is projected to trend towards 50% to 52% growth. Additionally, the AdvanceAD-Tx™ test, designed to guide systemic treatment for atopic dermatitis, received assay approval from the New York State Department of Health on July 14, 2026, expanding its availability to patients in New York. This test had previously won the "Genomics Innovation Award" on May 12, 2026.
3. New clinical evidence reinforced test accuracy, further solidifying analyst confidence and price targets. On September 9, 2026, a multi-center study published in the Journal of the American Academy of Dermatology validated the integrated DecisionDx-SCC test (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC), demonstrating its ability to significantly stratify patients by metastatic and local recurrence risk (p<0.0001) and improve predictive accuracy. This clinical validation, coupled with strong earnings, contributed to a positive sentiment from financial analysts. For instance, BTIG raised its price target for Castle Biosciences to $44 from $40, maintaining a Buy rating. As of late August 2026, analysts had a "Strong Buy" consensus rating for CSTL, with an average 12-month price target of $44.0, indicating a potential upside of 31.46% to 34.52%.
4. Castle Biosciences undertook a strategic dual listing on Nasdaq Texas. On August 17, 2026, the company announced its approval for dual listing on Nasdaq Texas, a new exchange. This move allows the company to maintain its primary listing on the Nasdaq Global Market while potentially enhancing its visibility, liquidity, and access to a broader investor base.
Show less
Castle Biosciences (CSTL) stock has gained about 55% since 5/31/2026 because of the following key factors:
1. Castle Biosciences (CSTL) significantly exceeded fiscal Q2 2026 earnings expectations and raised its full-year revenue guidance. The company reported fiscal Q2 2026 (ended June 30, 2026) earnings on July 30, 2026, with an adjusted loss per share of -$0.07, substantially better than analysts' consensus estimate of -$0.41. Revenue for the quarter reached $103.5 million, surpassing analyst projections of approximately $86.23 million to $86.4 million. Following these results, management increased its full-year 2026 revenue guidance to a range of $365 million to $375 million, up from the previous range of $345 million to $355 million, representing a $20 million increase at the midpoint. The company also projected achieving positive Adjusted EBITDA for fiscal Q3 2026, Q4 2026, and the full year 2026. This strong financial performance and optimistic outlook contributed to a favorable market response, with the stock closing up 9.32% on the day of the announcement and gaining another 7.28% in after-hours trading.
2. Key diagnostic tests demonstrated robust volume growth and expanded market access through regulatory approvals. The TissueCypher® Barrett's Esophagus test showed significant momentum, with 14,988 test reports delivered in fiscal Q2 2026, marking a 63% year-over-year increase compared to fiscal Q2 2025. Full-year volume for TissueCypher is projected to trend towards 50% to 52% growth. Additionally, the AdvanceAD-Tx™ test, designed to guide systemic treatment for atopic dermatitis, received assay approval from the New York State Department of Health on July 14, 2026, expanding its availability to patients in New York. This test had previously won the "Genomics Innovation Award" on May 12, 2026.
3. New clinical evidence reinforced test accuracy, further solidifying analyst confidence and price targets. On September 9, 2026, a multi-center study published in the Journal of the American Academy of Dermatology validated the integrated DecisionDx-SCC test (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC), demonstrating its ability to significantly stratify patients by metastatic and local recurrence risk (p<0.0001) and improve predictive accuracy. This clinical validation, coupled with strong earnings, contributed to a positive sentiment from financial analysts. For instance, BTIG raised its price target for Castle Biosciences to $44 from $40, maintaining a Buy rating. As of late August 2026, analysts had a "Strong Buy" consensus rating for CSTL, with an average 12-month price target of $44.0, indicating a potential upside of 31.46% to 34.52%.
4. Castle Biosciences undertook a strategic dual listing on Nasdaq Texas. On August 17, 2026, the company announced its approval for dual listing on Nasdaq Texas, a new exchange. This move allows the company to maintain its primary listing on the Nasdaq Global Market while potentially enhancing its visibility, liquidity, and access to a broader investor base.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 53.4% change in CSTL stock from 5/31/2026 to 9/12/2026 was primarily driven by a 48.4% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.08 | 32.33 | 53.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 340 | 357 | 5.1% |
| P/S Multiple | 1.9 | 2.8 | 48.4% |
| Shares Outstanding (Mil) | 30 | 30 | -1.7% |
| Cumulative Contribution | 53.4% |
Market Drivers
5/31/2026 to 9/12/2026| Return | Correlation | |
|---|---|---|
| CSTL | 53.4% | |
| Market (SPY) | 1.0% | 22.4% |
| Sector (XLV) | 10.6% | 24.9% |
Fundamental Drivers
The 9.3% change in CSTL stock from 2/28/2026 to 9/12/2026 was primarily driven by a 9.1% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.57 | 32.33 | 9.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 344 | 357 | 3.8% |
| P/S Multiple | 2.5 | 2.8 | 9.1% |
| Shares Outstanding (Mil) | 29 | 30 | -3.5% |
| Cumulative Contribution | 9.3% |
Market Drivers
2/28/2026 to 9/12/2026| Return | Correlation | |
|---|---|---|
| CSTL | 9.3% | |
| Market (SPY) | 11.7% | 28.3% |
| Sector (XLV) | 3.6% | 25.5% |
Fundamental Drivers
The 34.7% change in CSTL stock from 8/31/2025 to 9/12/2026 was primarily driven by a 37.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.01 | 32.33 | 34.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 346 | 357 | 3.2% |
| P/S Multiple | 2.0 | 2.8 | 37.2% |
| Shares Outstanding (Mil) | 29 | 30 | -4.9% |
| Cumulative Contribution | 34.7% |
Market Drivers
8/31/2025 to 9/12/2026| Return | Correlation | |
|---|---|---|
| CSTL | 34.7% | |
| Market (SPY) | 19.5% | 20.1% |
| Sector (XLV) | 21.9% | 24.8% |
Fundamental Drivers
The 62.2% change in CSTL stock from 8/31/2023 to 9/12/2026 was primarily driven by a 113.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9122026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.93 | 32.33 | 62.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 168 | 357 | 113.3% |
| P/S Multiple | 3.2 | 2.8 | -13.5% |
| Shares Outstanding (Mil) | 27 | 30 | -12.1% |
| Cumulative Contribution | 62.2% |
Market Drivers
8/31/2023 to 9/12/2026| Return | Correlation | |
|---|---|---|
| CSTL | 62.2% | |
| Market (SPY) | 75.7% | 25.3% |
| Sector (XLV) | 30.0% | 25.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CSTL Return | -36% | -45% | -8% | 23% | 46% | -17% | -52% |
| Peers Return | -8% | -59% | 36% | 37% | 40% | 20% | 19% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| CSTL Win Rate | 42% | 42% | 50% | 50% | 50% | 44% | |
| Peers Win Rate | 48% | 27% | 53% | 52% | 50% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| CSTL Max Drawdown | -60% | -66% | -59% | -31% | -55% | -58% | |
| Peers Max Drawdown | -45% | -68% | -41% | -35% | -50% | -40% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NEO, VCYT, MYGN, NTRA, GH. See CSTL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/11/2026 (YTD)
How Low Can It Go
| Event | CSTL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.9% | -18.8% |
| % Gain to Breakeven | 72.1% | 23.1% |
| Time to Breakeven | 161 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.3% | -9.5% |
| % Gain to Breakeven | 25.5% | 10.5% |
| Time to Breakeven | 19 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -55.1% | -6.7% |
| % Gain to Breakeven | 122.8% | 7.1% |
| Time to Breakeven | 429 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.6% | -33.7% |
| % Gain to Breakeven | 38.1% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
In The Past
Castle Biosciences's stock fell -41.9% during the 2025 US Tariff Shock. Such a loss loss requires a 72.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CSTL | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -41.9% | -18.8% |
| % Gain to Breakeven | 72.1% | 23.1% |
| Time to Breakeven | 161 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.3% | -9.5% |
| % Gain to Breakeven | 25.5% | 10.5% |
| Time to Breakeven | 19 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -55.1% | -6.7% |
| % Gain to Breakeven | 122.8% | 7.1% |
| Time to Breakeven | 429 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.6% | -33.7% |
| % Gain to Breakeven | 38.1% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
In The Past
Castle Biosciences's stock fell -41.9% during the 2025 US Tariff Shock. Such a loss loss requires a 72.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Castle Biosciences (CSTL)
```html
Castle Biosciences (CSTL) is a commercial-stage diagnostics company specializing in the development and provision of advanced genetic tests for dermatological cancers. The company's core mission is to offer physicians and their patients critical diagnostic and prognostic information through multi-gene expression profile (GEP) tests. These tests provide insights into an individual patient's tumor biology, helping to assess the risk of cancer metastasis and aiding in more informed treatment decisions for various skin and eye cancers.
The company's main product portfolio includes several proprietary GEP tests. DecisionDx-Melanoma is designed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. For those with uveal melanoma, a rare eye cancer, Castle Biosciences offers DecisionDx-UM to predict metastasis risk. Another key product, DecisionDx-SCC, is a 40-gene expression profile test used to predict the individual risk of squamous cell carcinoma metastasis in patients with specific risk factors. Additionally, the company provides DecisionDx DiffDx-Melanoma and myPath Melanoma, which are GEP tests utilized for the accurate diagnosis of suspicious pigmented lesions.
Castle Biosciences primarily serves the medical community, with its services targeted at physicians and their patients who are facing diagnoses of dermatological cancers such as melanoma and squamous cell carcinoma, as well as those requiring diagnostic clarity for suspicious skin lesions. By delivering molecular insights into cancer biology, Castle Biosciences aims to enhance patient care through improved risk stratification and the facilitation of personalized treatment strategies in oncology.
```AI Analysis | Feedback
Here are a few brief analogies for Castle Biosciences (CSTL):
- A Foundation Medicine for predicting the spread of skin and eye cancers.
- Like an Invitae or Natera, but specializing in gene expression tests to forecast metastasis risk in skin and eye cancers.
AI Analysis | Feedback
- DecisionDx-Melanoma: A multi-gene expression profile (GEP) test designed to identify the risk of metastasis for patients with invasive cutaneous melanoma.
- DecisionDx-UM: A proprietary GEP test used to predict the risk of metastasis for patients diagnosed with uveal melanoma.
- DecisionDx-SCC: A proprietary 40-gene expression profile test that predicts the individual risk of squamous cell carcinoma metastasis for patients with specific risk factors.
- DecisionDx DiffDx-Melanoma and myPath Melanoma: Proprietary GEP tests utilized for the diagnosis of suspicious pigmented lesions.
AI Analysis | Feedback
Castle Biosciences (CSTL) primarily offers its diagnostic and prognostic testing services to healthcare providers who, in turn, utilize these services for their patients. Therefore, its major customers are not individual consumers, but rather medical professionals and the institutions they represent.
Here are the primary categories of customers Castle Biosciences serves:
- Dermatologists and Dermatology Practices: These are key customers as the company's lead products, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, and myPath Melanoma, focus on diagnosing and predicting the risk of metastasis for dermatological cancers like cutaneous melanoma and squamous cell carcinoma. Dermatologists are typically the first point of contact for patients with suspicious lesions and make decisions regarding further testing.
- Ophthalmologists and Ocular Oncology Practices: For its DecisionDx-UM test, which predicts the risk of metastasis for patients with uveal melanoma (a rare eye cancer), ophthalmologists, particularly those specializing in ocular oncology, are crucial customers who order these specialized tests.
- Oncologists and Hospitals/Integrated Healthcare Systems: Oncologists, particularly those specializing in melanoma or skin cancers, may utilize Castle Biosciences' tests for risk stratification and management of high-risk patients. Additionally, hospitals and larger integrated healthcare systems encompassing dermatology, ophthalmology, and oncology departments are significant customers, as they provide comprehensive care and often have established pathways for ordering specialized diagnostic tests.
AI Analysis | Feedback
null
AI Analysis | Feedback
Derek J. Maetzold, President and Chief Executive Officer
Derek J. Maetzold founded Castle Biosciences in September 2007, initiating operations in late 2008 with co-founders Toby Juvenal and Kristen Oelschlager. Before founding Castle Biosciences, he accumulated 24 years of experience in pharmaceutical development and commercialization, focusing on new product development through business licensing and commercial oversight of pre-approved therapies. Immediately prior to starting Castle, he prepared a public biotechnology company for its first commercial product launch, and this company was subsequently sold. His pharmaceutical career involved leadership roles at companies such as Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals, and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold has contributed to the discovery, development, and commercialization of five diagnostic and prognostic tests in cancers and is a co-inventor of multiple technologies at Castle Biosciences and Encysive Pharmaceuticals.
Frank Stokes, Chief Financial Officer
Frank Stokes has served as Castle Biosciences' Chief Financial Officer since December 2017. Prior to joining Castle Biosciences, he was the Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company, where he was involved in the company's initial capitalization and the acquisition of its foundational drug delivery technology. Mr. Stokes also had a distinguished career as a senior investment banker at firms including Leerink Partners (now SVB Leerink), Robert W. Baird, and Wachovia Securities (now Wells Fargo Securities). In these roles, he led life sciences, tools, and diagnostics sector investment banking efforts, and managed various financings, and mergers and acquisitions transactions. He successfully stewarded Castle through its IPO in 2019, a move he had actively anticipated and pursued a relationship with Castle for during his banking career.
Kristen M. Oelschlager, Chief Operating Officer
Kristen M. Oelschlager joined Castle Biosciences in October 2008 as one of the company's three initial employees, serving as the Executive Director of Operations. She has held the position of Chief Operating Officer since April 2021, and her previous roles at Castle Biosciences include Chief Operations Officer (August 2020 to April 2021), Senior Vice President, Clinical Operations (January 2018 to August 2020), and Vice President, Clinical Operations (2013 to 2018). Ms. Oelschlager brings over 15 years of experience in clinical nursing, clinical operations services, and clinical research to her role.
Tobin W. Juvenal, Chief Commercial Officer
Tobin W. Juvenal was one of the three initial employees at Castle Biosciences, joining in October 2008 as the Executive Director, Sales and Marketing. He has served as Chief Commercial Officer since September 2020. His prior roles at the company include Senior Vice President, Sales (January 2018 to August 2020), and Vice President of Sales (2013 to 2018).
AI Analysis | Feedback
Here are the key risks to Castle Biosciences (CSTL):
- Reimbursement Uncertainty and Challenges: Castle Biosciences faces significant risk from ongoing uncertainties and potential changes in reimbursement policies for its diagnostic tests. Management has acknowledged uncertainty, particularly for AdvanceAD-Tx and DecisionDx-SCC. Notably, a Medicare contractor, Novitas, finalized a decision for non-coverage of the DecisionDx-SCC test, which became effective in February 2025. This non-coverage is considered a "material risk to one of CSTL's highest-growth assets," potentially eliminating Medicare reimbursement for a key product. The company's financial outlook and ability to translate test volumes into sustainable earnings are highly dependent on favorable reimbursement decisions and payer coverage.
- Concentration Risk on Key Products: While Castle Biosciences is expanding its portfolio, a substantial portion of its revenue is expected to continue coming from its core DecisionDx-Melanoma franchise and related dermatologic tests for the foreseeable future. This reliance on a limited number of products exposes the company to significant risk if new competitors emerge, reimbursement rates are cut for these specific tests, or new clinical guidelines reduce their utility or adoption.
- Persistent Net Losses and Challenges to Profitability: Despite experiencing strong top-line revenue growth and increasing test volumes, Castle Biosciences has consistently reported net losses. The company recorded a net loss of $24.2 million for the full year 2025. High operating expenses, which are growing faster than revenue, contribute to operational inefficiencies and a challenging path to sustained profitability. While the company maintains a strong gross margin, its negative earnings per share and net margin highlight ongoing difficulties in translating revenue into positive net income.
AI Analysis | Feedback
The emergence of artificial intelligence (AI) and machine learning (ML) powered digital pathology solutions that can analyze routine histology slides to predict metastatic risk for dermatological cancers. Such solutions could provide prognostic information directly from existing tissue biopsies (e.g., H&E stained slides), potentially offering a faster, more cost-effective, and integrated alternative to specialized multi-gene expression profile (GEP) tests like those offered by Castle Biosciences, thereby reducing the demand for their proprietary testing services.
AI Analysis | Feedback
Castle Biosciences addresses significant markets with its diagnostic and prognostic tests for dermatological cancers:
- DecisionDx-Melanoma: The estimated addressable market for DecisionDx-Melanoma in the U.S. is approximately 130,000 eligible patients diagnosed with invasive cutaneous melanoma annually. The broader U.S. melanoma diagnostics and therapeutics market was valued at an estimated USD 3.45 billion in 2025 and is projected to reach USD 5.21 billion by 2030. Globally, the melanoma cancer diagnostics market was valued at USD 4.95 billion in 2024 and is expected to grow to USD 8.64 billion by 2032.
- DecisionDx-UM: The global uveal melanoma market was valued at USD 1.5 billion in 2024 and is projected to grow to USD 2.5 billion by 2034. Another report estimates the global uveal melanoma market at USD 402.5 million in 2024, expected to reach USD 609.7 million by 2030. North America, particularly the U.S., dominates this market, with about 2,500 individuals diagnosed annually in the U.S. The uveal melanoma treatment market in North America held the largest revenue share of 44.2% in 2024.
- DecisionDx-SCC: The estimated total addressable market for DecisionDx-SCC in the U.S. is approximately 200,000 patients diagnosed annually with high-risk squamous cell carcinoma. The squamous cell carcinoma market across the top 7 major markets (U.S., EU4, U.K., and Japan) was valued at USD 739.1 million in 2024 and is projected to reach USD 1,469.0 million by 2035. The global cutaneous squamous cell carcinoma treatment market size is estimated at USD 13.69 billion in 2024 and is projected to reach approximately USD 27.54 billion by 2034. The United States accounts for the largest market size in Cutaneous Squamous Cell Carcinoma.
- DecisionDx DiffDx-Melanoma and myPath Melanoma: These tests, combined as Castle's Diagnostic GEP offering for difficult-to-diagnose melanocytic lesions, represent an estimated U.S. total addressable market of $600 million. The clinical offering of DiffDx-Melanoma was suspended in February 2023, with myPath Melanoma continuing.
AI Analysis | Feedback
Castle Biosciences (CSTL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
-
Increased Adoption and Penetration of Core Dermatology Tests: Continued growth is anticipated from the company's flagship dermatological tests, particularly DecisionDx-Melanoma. In 2025, DecisionDx-Melanoma delivered 39,083 test reports, showing a 9% year-over-year increase, and achieved approximately 31% patient penetration with nearly 17,000 ordering clinicians. The company is also working on a de novo 510(k) submission to support commercial reimbursement.
-
Expansion of TissueCypher Barrett's Esophagus Test: The TissueCypher test, which identifies the risk of progression for patients with Barrett's esophagus, is a significant growth driver. Its test volume grew 86% to 39,014 reports in 2025, with management noting only about 11% patient penetration, indicating substantial room for future expansion. The test's inclusion in the AGA Barrett's esophagus guideline further supports its adoption.
-
Commercialization of AdvanceAD-Tx for Atopic Dermatitis: Castle Biosciences launched AdvanceAD-Tx, a gene expression profile test for moderate-to-severe atopic dermatitis, on a limited-access basis in November 2025. Early results showed strong interest, with over half of the initial 150 dermatological accounts ordering the test within the first five weeks. This new product is expected to materially expand the company's total addressable market, with significant revenue contributions anticipated in 2027 or 2028 as reimbursement pathways are established and availability expands.
-
Strategic Commercial Team Expansion and Market Penetration: The company plans to enhance its commercial efforts, including potential expansion of its sales force, to drive broader adoption by both clinicians and payers for its existing and newly launched products. This strategic focus aims to capitalize on unmet clinical needs and significant market opportunities through robust clinical evidence and targeted penetration.
AI Analysis | Feedback
Share Issuance
- Castle Biosciences' common shares issued and outstanding have steadily increased over the last few years, reflecting ongoing share issuances.
- As of December 31, 2020, there were 24,812,487 shares issued and outstanding, increasing to 25,054,513 shares by March 31, 2021.
- The number of shares issued and outstanding further grew to 26,553,681 by December 31, 2022, and approximately 30 million shares by the fourth quarter of 2025.
Capital Expenditures
- Capital expenditures totaled $31.0 million in 2025 and $9.3 million in 2024.
- The capital expenditures in 2024 and 2025 were primarily related to a development project for a new building.
- The company anticipates that capital expenditures will decline in 2026.
Peer Outperformance in Life Sciences Tools & Services
CSTL has outperformed 62% of its 108 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it is GH. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that CSTL has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
80%
of 127 industry peers · 50.9% return
3Y
80%
of 117 industry peers · 74.7% return
5Y
62%
of 108 industry peers · -55.8% return
Life Sciences Tools & Services peers with revenue growth within 4pp of CSTL's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| CSTL | Castle Biosciences | 31.8% | -50.6x | 50.9% | 74.7% | -55.8% | — |
| GH | Guardant Health | 32.6% | -46.1x | 186.7% | 388.0% | 24.4% | +80pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is CSTL's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 7.1% | 86.6% | 123.6% | CAH 394% · MCK 338% · COR 174% |
| Managed Health Care | 8 | 43.7% | -1.7% | 5.5% | OSCR 92% · HQY 50% · ELV 22% |
| Health Care Services | 20 | 18.9% | 44.9% | -1.2% | HIMS 210% · RDNT 167% · DGX 68% |
| Health Care Facilities | 24 | 3.7% | 8.8% | -15.4% | NHC 274% · THC 258% · ENSG 119% |
| Health Care Equipment | 50 | -1.7% | -5.7% | -25.4% | POCI 10800% · UFPT 324% · GKOS 233% |
| Health Care Supplies | 12 | 20.8% | -12.4% | -38.0% | LNTH 300% · HAE 51% · MMSI 21% |
| Pharmaceuticals | 62 | -7.4% | 7.5% | -41.2% | LQDA 2363% · INDV 1136% · ETON 1026% |
| Life Sciences Tools & Services ← | 109 | -1.4% | -26.6% | -71.9% | SNWV 1573% · MEDP 217% · NTRA 174% |
| Health Care Technology | 20 | -31.7% | -51.5% | -79.2% | SPOK 79% · HSTM 2% · VEEV -12% |
| Biotechnology | 361 | 1.6% | -25.2% | -79.6% | DNTH 1596% · CELZ 1272% · ELVN 1178% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 36.60 |
| Mkt Cap | 2.8 |
| Rev LTM | 786 |
| Op Inc LTM | -76 |
| FCF LTM | -4 |
| FCF 3Y Avg | -3 |
| CFO LTM | 32 |
| CFO 3Y Avg | 30 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.2% |
| Rev Chg 3Y Avg | 25.7% |
| Rev Chg Q | 17.8% |
| QoQ Delta Rev Chg LTM | 4.4% |
| Op Inc Chg LTM | -0.4% |
| Op Inc Chg 3Y Avg | 16.2% |
| Op Mgn LTM | -9.8% |
| Op Mgn 3Y Avg | -11.6% |
| QoQ Delta Op Mgn LTM | 1.2% |
| CFO/Rev LTM | 5.7% |
| CFO/Rev 3Y Avg | 3.1% |
| FCF/Rev LTM | -0.5% |
| FCF/Rev 3Y Avg | -1.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Delivery of test reports for our molecular diagnostic tests | 344 | 332 | 220 | 137 | |
| Dermatologic | 86 | ||||
| Non-Dermatologic | 8 | ||||
| Total | 344 | 332 | 220 | 137 | 94 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Delivery of test reports for our molecular diagnostic tests | -24 | 18 | -57 | -67 |
| Total | -24 | 18 | -57 | -67 |
Price Behavior
Price Behavior
| Market Price | $32.33 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 07/25/2019 | |
| Distance from 52W High | -24.9% | |
| 50 Days | 200 Days | |
| DMA Price | $28.71 | $29.31 |
| DMA Trend | up | up |
| Distance from DMA | 12.6% | 10.3% |
| 3M | 1YR | |
| Volatility | 50.9% | 56.2% |
| Downside Capture | 4.17 | 101.90 |
| Upside Capture | 224.74 | 131.31 |
| Correlation (SPY) | 26.2% | 21.3% |
CSTL Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.78 | 2.15 | 0.99 | 1.24 | 0.92 | 1.01 |
| Up Beta | 1.68 | 4.02 | 2.11 | 1.96 | 1.63 | 1.10 |
| Down Beta | -1.56 | -2.12 | 0.11 | 0.52 | -0.32 | 0.81 |
| Up Capture | 476% | 381% | 212% | 124% | 139% | 114% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 22 | 33 | 64 | 132 | 370 |
| Down Capture | 278% | 128% | -25% | 119% | 106% | 102% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 20 | 30 | 62 | 118 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CSTL | |
|---|---|---|---|---|
| CSTL | 41.1% | 56.3% | 0.82 | - |
| Sector ETF (XLV) | 22.1% | 16.2% | 1.04 | 24.0% |
| Equity (SPY) | 18.3% | 12.8% | 1.03 | 21.0% |
| Gold (GLD) | 19.0% | 29.2% | 0.59 | 6.6% |
| Commodities (DBC) | 48.3% | 20.6% | 1.80 | -18.2% |
| Real Estate (VNQ) | 7.6% | 13.6% | 0.29 | 12.3% |
| Bitcoin (BTCUSD) | -32.4% | 43.8% | -0.77 | 14.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CSTL | |
|---|---|---|---|---|
| CSTL | -15.6% | 74.1% | 0.10 | - |
| Sector ETF (XLV) | 5.5% | 15.2% | 0.18 | 26.8% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 33.2% |
| Gold (GLD) | 18.7% | 18.8% | 0.81 | 5.2% |
| Commodities (DBC) | 11.4% | 19.5% | 0.46 | 1.4% |
| Real Estate (VNQ) | 0.7% | 18.9% | -0.07 | 31.1% |
| Bitcoin (BTCUSD) | 9.4% | 52.6% | 0.36 | 24.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CSTL | |
|---|---|---|---|---|
| CSTL | 4.5% | 73.6% | 0.41 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | 25.0% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 29.1% |
| Gold (GLD) | 12.3% | 16.3% | 0.62 | 7.3% |
| Commodities (DBC) | 8.7% | 18.1% | 0.39 | 4.0% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 24.1% |
| Bitcoin (BTCUSD) | 63.2% | 66.2% | 1.03 | 21.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/1/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | 4.5% | 13.7% | 25.0% |
| 5/6/2026 | -22.3% | -26.7% | -15.1% |
| 2/26/2026 | -7.2% | -12.5% | -26.2% |
| 11/3/2025 | 21.7% | 33.7% | 52.4% |
| 8/4/2025 | 32.8% | 25.1% | 51.4% |
| 5/5/2025 | -11.4% | -9.1% | -9.2% |
| 2/27/2025 | -14.2% | -18.6% | -21.1% |
| 11/4/2024 | -7.4% | 0.4% | -5.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 15 | 18 |
| # Negative | 14 | 13 | 10 |
| Median Positive | 7.1% | 5.3% | 18.2% |
| Median Negative | -7.4% | -12.0% | -10.0% |
| Max Positive | 32.8% | 33.7% | 52.4% |
| Max Negative | -26.0% | -27.0% | -26.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | 4.5% | 13.7% | 25.0% |
| 5/6/2026 | -22.3% | -26.7% | -15.1% |
| 2/26/2026 | -7.2% | -12.5% | -26.2% |
| 11/3/2025 | 21.7% | 33.7% | 52.4% |
| 8/4/2025 | 32.8% | 25.1% | 51.4% |
| 5/5/2025 | -11.4% | -9.1% | -9.2% |
| 2/27/2025 | -14.2% | -18.6% | -21.1% |
| 11/4/2024 | -7.4% | 0.4% | -5.2% |
| 8/5/2024 | 14.0% | 22.4% | 32.3% |
| 5/2/2024 | 6.5% | 6.9% | 2.5% |
| 2/28/2024 | -26.0% | -12.0% | -9.2% |
| 1/8/2024 | 4.1% | -4.6% | 14.2% |
| 11/2/2023 | 8.0% | 2.9% | 19.8% |
| 8/2/2023 | 11.8% | 5.3% | 18.7% |
| 5/3/2023 | -3.9% | 1.3% | -0.8% |
| 2/28/2023 | -9.2% | -10.2% | -10.8% |
| 1/9/2023 | 2.5% | 19.3% | 17.6% |
| 11/2/2022 | -2.0% | -27.0% | 3.8% |
| 8/8/2022 | 7.6% | 17.6% | -6.2% |
| 5/9/2022 | 5.8% | 1.6% | 13.8% |
| 2/28/2022 | 7.9% | -4.6% | 5.8% |
| 1/10/2022 | 2.9% | -6.1% | 15.7% |
| 11/8/2021 | -10.2% | -14.8% | -25.6% |
| 8/9/2021 | -4.9% | -15.1% | 6.5% |
| 5/10/2021 | -0.4% | 1.9% | 29.4% |
| 3/8/2021 | -6.0% | -0.5% | 6.7% |
| 1/13/2021 | -7.4% | 3.1% | 19.2% |
| 11/9/2020 | 4.7% | 5.2% | 21.5% |
| SUMMARY STATS | |||
| # Positive | 14 | 15 | 18 |
| # Negative | 14 | 13 | 10 |
| Median Positive | 7.1% | 5.3% | 18.2% |
| Median Negative | -7.4% | -12.0% | -10.0% |
| Max Positive | 32.8% | 33.7% | 52.4% |
| Max Negative | -26.0% | -27.0% | -26.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/30/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/30/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/08/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/11/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/10/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Recent Forward Guidance
Updated 8/4/2026Latest: Q2 2026 Earnings Reported 7/30/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Adjusted EBITDA | Reported | |||||||
| Q4 2026 Adjusted EBITDA | Reported | |||||||
| 2026 Total Revenue | Reported | 365.00 Mil | 370.00 Mil | 375.00 Mil | 5.7% | Raised | Guidance: 350.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | |||||||
Prior: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 345.00 Mil | 350.00 Mil | 355.00 Mil | Raised | Guidance: 345.00 Mil for 2026 | ||
Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 340.00 Mil | 345.00 Mil | 350.00 Mil | 4.2% | Higher New | Guidance: 331.00 Mil for 2025 | |
Q3 2025 Earnings Reported 11/3/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | Reported | 327.00 Mil | 331.00 Mil | 335.00 Mil | 5.1% | Raised | Guidance: 315.00 Mil for 2025 | |
Insider Activity
Updated 9/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 9032026 | 33.39 | 4,152 | 138,643 | 445,981 | Form |
| 2 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 9022026 | 32.81 | 1,730 | 56,761 | 2,138,687 | Form |
| 3 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 9012026 | 33.20 | 12,428 | 412,571 | 713,037 | Form |
| 4 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 9012026 | 33.20 | 2,714 | 90,097 | 585,628 | Form |
| 5 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 9012026 | 33.20 | 2,306 | 76,552 | 497,786 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 9032026 | 33.39 | 4,152 | 138,643 | 445,981 | Form |
| 2 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 9022026 | 32.81 | 1,730 | 56,761 | 2,138,687 | Form |
| 3 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 9012026 | 33.20 | 12,428 | 412,571 | 713,037 | Form |
| 4 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 9012026 | 33.20 | 2,714 | 90,097 | 585,628 | Form |
| 5 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 9012026 | 33.20 | 2,306 | 76,552 | 497,786 | Form |
| 6 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 9012026 | 33.20 | 278 | 9,228 | 373,653 | Form |
| 7 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 9012026 | 33.20 | 278 | 9,228 | 373,653 | Form |
| 8 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 9012026 | 33.20 | 278 | 9,228 | 373,653 | Form |
| 9 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 9012026 | 33.20 | 278 | 9,228 | 373,653 | Form |
| 10 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 8272026 | 35.04 | 9,050 | 317,112 | 2,344,667 | Form |
| 11 | Oelschlager, Kristen M | Chief Operating Officer | The Fritz Shorter Trust | Sell | 8262026 | 34.42 | 12,384 | 426,277 | 2,500,693 | Form |
| 12 | Oelschlager, Kristen M | Chief Operating Officer | The Fritz Shorter Trust | Sell | 8262026 | 33.69 | 12,218 | 411,588 | 2,864,507 | Form |
| 13 | Stokes, Frank | Chief Financial Officer | Direct | Sell | 8182026 | 29.77 | 24,908 | 741,511 | 1,047,219 | Form |
| 14 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 8182026 | 30.02 | 1,100 | 33,022 | 644,800 | Form |
| 15 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 8182026 | 30.02 | 2,714 | 81,474 | 611,057 | Form |
| 16 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 8182026 | 30.02 | 2,306 | 69,226 | 519,376 | Form |
| 17 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 8182026 | 30.02 | 278 | 8,346 | 346,251 | Form |
| 18 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 8182026 | 30.02 | 278 | 8,346 | 346,251 | Form |
| 19 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 8182026 | 30.02 | 278 | 8,346 | 346,251 | Form |
| 20 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 8182026 | 30.02 | 278 | 8,346 | 346,251 | Form |
| 21 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 8062026 | 30.68 | 2,546 | 78,114 | 658,997 | Form |
| 22 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 8062026 | 30.68 | 556 | 17,059 | 707,780 | Form |
| 23 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 8062026 | 30.68 | 473 | 14,512 | 601,562 | Form |
| 24 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 8062026 | 31.11 | 20,356 | 633,261 | 668,197 | Form |
| 25 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 8062026 | 31.11 | 8,156 | 253,727 | 734,957 | Form |
| 26 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 8062026 | 31.11 | 6,929 | 215,557 | 624,675 | Form |
| 27 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 8062026 | 38.39 | 1,301 | 49,945 | 2,982,673 | Form |
| 28 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 8052026 | 29.77 | 8,586 | 255,622 | 395,610 | Form |
| 29 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 8042026 | 28.25 | 1,730 | 48,872 | 2,231,609 | Form |
| 30 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 8042026 | 30.35 | 10,664 | 323,684 | 651,952 | Form |
| 31 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 8042026 | 30.35 | 4,232 | 128,454 | 964,649 | Form |
| 32 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 8042026 | 30.35 | 3,597 | 109,180 | 819,804 | Form |
| 33 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 8042026 | 29.31 | 17,310 | 507,302 | 2,365,798 | Form |
| 34 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 8042026 | 30.15 | 6,480 | 195,385 | 647,635 | Form |
| 35 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 8042026 | 30.15 | 1,983 | 59,791 | 1,085,864 | Form |
| 36 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 8042026 | 30.15 | 1,690 | 50,957 | 922,832 | Form |
| 37 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 7292026 | 24.16 | 6,214 | 150,160 | 519,034 | Form |
| 38 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 7292026 | 24.16 | 1,357 | 32,791 | 918,145 | Form |
| 39 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 7292026 | 24.16 | 1,153 | 27,862 | 780,423 | Form |
| 40 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 7292026 | 24.16 | 278 | 6,717 | 285,419 | Form |
| 41 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 7292026 | 24.16 | 278 | 6,717 | 285,419 | Form |
| 42 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 7292026 | 24.16 | 278 | 6,717 | 285,419 | Form |
| 43 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 7292026 | 24.16 | 278 | 6,717 | 285,419 | Form |
| 44 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 7162026 | 22.92 | 550 | 12,606 | 492,299 | Form |
| 45 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 7162026 | 22.92 | 1,357 | 31,102 | 901,971 | Form |
| 46 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 7162026 | 22.92 | 1,153 | 26,427 | 766,651 | Form |
| 47 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 7162026 | 22.92 | 278 | 6,372 | 277,103 | Form |
| 48 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 7162026 | 22.92 | 278 | 6,372 | 277,103 | Form |
| 49 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 7162026 | 22.92 | 278 | 6,372 | 277,103 | Form |
| 50 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 7162026 | 22.92 | 278 | 6,372 | 277,103 | Form |
| 51 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 7062026 | 24.29 | 6,214 | 150,938 | 521,725 | Form |
| 52 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 7062026 | 24.29 | 1,357 | 32,962 | 988,846 | Form |
| 53 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 7062026 | 24.29 | 1,153 | 28,006 | 840,483 | Form |
| 54 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 7062026 | 24.29 | 278 | 6,753 | 300,419 | Form |
| 55 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 7062026 | 24.29 | 278 | 6,753 | 300,419 | Form |
| 56 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 7062026 | 24.29 | 278 | 6,753 | 300,419 | Form |
| 57 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 7062026 | 24.29 | 278 | 6,753 | 300,419 | Form |
| 58 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 7062026 | 24.42 | 8,586 | 209,650 | 534,113 | Form |
| 59 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 6172026 | 20.66 | 550 | 11,363 | 443,756 | Form |
| 60 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 6172026 | 20.66 | 1,357 | 28,036 | 869,104 | Form |
| 61 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 6172026 | 20.66 | 1,153 | 23,821 | 738,698 | Form |
| 62 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 6172026 | 20.66 | 278 | 5,743 | 261,266 | Form |
| 63 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 6172026 | 20.66 | 278 | 5,743 | 261,266 | Form |
| 64 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 6172026 | 20.66 | 278 | 5,743 | 261,266 | Form |
| 65 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 6172026 | 20.66 | 278 | 5,743 | 261,266 | Form |
| 66 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 6032026 | 20.86 | 6,214 | 129,605 | 447,988 | Form |
| 67 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 6032026 | 20.86 | 1,357 | 28,303 | 905,694 | Form |
| 68 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 6032026 | 20.86 | 1,153 | 24,048 | 769,790 | Form |
| 69 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 6032026 | 20.86 | 278 | 5,798 | 34,789 | Form |
| 70 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 6032026 | 20.86 | 278 | 5,798 | 34,789 | Form |
| 71 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 6032026 | 20.86 | 278 | 5,798 | 34,789 | Form |
| 72 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 6032026 | 20.86 | 278 | 5,798 | 34,789 | Form |
| 73 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 5222026 | 20.20 | 420 | 8,482 | 433,790 | Form |
| 74 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 5222026 | 20.20 | 1,035 | 20,903 | 904,397 | Form |
| 75 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 5222026 | 20.20 | 880 | 17,772 | 768,680 | Form |
| 76 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 5222026 | 20.20 | 212 | 4,282 | 39,301 | Form |
| 77 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 5222026 | 20.20 | 212 | 4,282 | 39,301 | Form |
| 78 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 5222026 | 20.20 | 212 | 4,282 | 39,301 | Form |
| 79 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 5222026 | 20.20 | 212 | 4,282 | 39,301 | Form |
| 80 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 5222026 | 20.00 | 130 | 2,600 | 429,623 | Form |
| 81 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 5222026 | 20.00 | 322 | 6,441 | 916,412 | Form |
| 82 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 5222026 | 20.00 | 273 | 5,461 | 778,898 | Form |
| 83 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 5222026 | 20.00 | 66 | 1,320 | 43,164 | Form |
| 84 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 5222026 | 20.00 | 66 | 1,320 | 43,164 | Form |
| 85 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 5222026 | 20.00 | 66 | 1,320 | 43,164 | Form |
| 86 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 5222026 | 20.00 | 66 | 1,320 | 43,164 | Form |
| 87 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 5112026 | 22.15 | 6,214 | 137,663 | 475,838 | Form |
| 88 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 5112026 | 22.15 | 1,357 | 30,063 | 1,022,127 | Form |
| 89 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 5112026 | 22.15 | 1,153 | 25,543 | 868,731 | Form |
| 90 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 5112026 | 22.15 | 278 | 6,159 | 49,272 | Form |
| 91 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 5112026 | 22.15 | 278 | 6,159 | 49,272 | Form |
| 92 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 5112026 | 22.15 | 278 | 6,159 | 49,272 | Form |
| 93 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 5112026 | 22.15 | 278 | 6,159 | 49,272 | Form |
| 94 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 4232026 | 25.10 | 550 | 13,804 | 539,080 | Form |
| 95 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 4232026 | 25.10 | 1,357 | 34,058 | 1,192,030 | Form |
| 96 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 4232026 | 25.10 | 1,153 | 28,938 | 1,013,131 | Form |
| 97 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 4232026 | 25.10 | 278 | 6,977 | 62,795 | Form |
| 98 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 4232026 | 25.10 | 278 | 6,977 | 62,795 | Form |
| 99 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 4232026 | 25.10 | 278 | 6,977 | 62,795 | Form |
| 100 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 4232026 | 25.10 | 278 | 6,977 | 62,795 | Form |
| 101 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 4082026 | 25.03 | 6,214 | 155,536 | 537,619 | Form |
| 102 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 4082026 | 25.03 | 1,357 | 33,966 | 1,222,766 | Form |
| 103 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 4082026 | 25.03 | 1,153 | 28,860 | 1,039,246 | Form |
| 104 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 4082026 | 25.03 | 278 | 6,958 | 69,583 | Form |
| 105 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 4082026 | 25.03 | 278 | 6,958 | 69,583 | Form |
| 106 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 4082026 | 25.03 | 278 | 6,958 | 69,583 | Form |
| 107 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 4082026 | 25.03 | 278 | 6,958 | 69,583 | Form |
| 108 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 3302026 | 25.55 | 550 | 14,053 | 548,810 | Form |
| 109 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 3302026 | 25.55 | 1,357 | 34,673 | 1,282,890 | Form |
| 110 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 3302026 | 25.55 | 1,153 | 29,460 | 1,090,338 | Form |
| 111 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 3302026 | 25.55 | 278 | 7,103 | 78,135 | Form |
| 112 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 3302026 | 25.55 | 278 | 7,103 | 78,135 | Form |
| 113 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 3302026 | 25.55 | 278 | 7,103 | 78,135 | Form |
| 114 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 3302026 | 25.55 | 278 | 7,103 | 78,135 | Form |
| 115 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 3172026 | 25.97 | 17,575 | 456,408 | 1,058,995 | Form |
| 116 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 3172026 | 25.45 | 13,204 | 336,002 | 1,484,934 | Form |
| 117 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 3162026 | 25.24 | 20,863 | 526,582 | 2,191,463 | Form |
| 118 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 3132026 | 25.28 | 23,179 | 585,942 | 1,808,915 | Form |
| 119 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 3132026 | 26.11 | 17,310 | 451,947 | 2,473,488 | Form |
| 120 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold Descendants 2020 Trust | Sell | 3132026 | 26.11 | 1,357 | 35,430 | 1,346,337 | Form |
| 121 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Derek Maetzold 2020 Irrevocable Trust | Sell | 3132026 | 26.11 | 1,160 | 30,286 | 1,144,253 | Form |
| 122 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk | Sell | 3132026 | 26.11 | 282 | 7,363 | 87,100 | Form |
| 123 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold | Sell | 3132026 | 26.11 | 279 | 7,284 | 87,100 | Form |
| 124 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO John Derek Maetzold | Sell | 3132026 | 26.11 | 279 | 7,284 | 87,100 | Form |
| 125 | Maetzold, Derek J | Pres. & Chief Exec. Officer | The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold | Sell | 3132026 | 26.11 | 279 | 7,284 | 87,100 | Form |
| 126 | Stokes, Frank | Chief Financial Officer | Direct | Sell | 3092026 | 27.98 | 6,001 | 167,908 | 1,681,178 | Form |
| 127 | Cole, G Bradley | Direct | Sell | 3092026 | 28.47 | 7,403 | 210,727 | 549,633 | Form | |
| 128 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 2052026 | 37.99 | 817 | 31,035 | 3,179,430 | Form |
| 129 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 2052026 | 39.91 | 3,200 | 127,722 | 3,373,247 | Form |
| 130 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 1222026 | 40.01 | 4,017 | 160,732 | 3,509,740 | Form |
| 131 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12292025 | 40.35 | 830 | 33,490 | 1,352,936 | Form |
| 132 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12192025 | 40.04 | 509 | 20,380 | 1,375,774 | Form |
| 133 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 12192025 | 39.31 | 14,888 | 585,292 | 484,454 | Form |
| 134 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12172025 | 38.55 | 12,821 | 494,301 | 1,344,339 | Form |
| 135 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12172025 | 38.78 | 19,525 | 757,099 | 1,849,221 | Form |
| 136 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 12152025 | 37.48 | 13,200 | 494,736 | 3,254,201 | Form |
| 137 | Stokes, Frank | Chief Financial Officer | Direct | Sell | 12152025 | 37.45 | 4,496 | 168,375 | 1,884,709 | Form |
| 138 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12082025 | 40.03 | 1,339 | 53,600 | 1,503,006 | Form |
| 139 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12042025 | 39.23 | 2,678 | 105,058 | 1,525,498 | Form |
| 140 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 12012025 | 40.09 | 4,258 | 170,703 | 1,666,301 | Form |
| 141 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 11262025 | 40.05 | 5,115 | 204,851 | 1,835,125 | Form |
| 142 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 11242025 | 35.58 | 4,693 | 166,977 | 3,009,890 | Form |
| 143 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 11202025 | 34.02 | 2,678 | 91,106 | 1,732,877 | Form |
| 144 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 11132025 | 35.40 | 200 | 7,080 | 2,967,476 | Form |
| 145 | Stokes, Frank | Chief Financial Officer | Direct | Sell | 11132025 | 35.08 | 5,388 | 189,011 | 1,519,946 | Form |
| 146 | Juvenal, Tobin W | Chief Commercial Officer | Direct | Sell | 11132025 | 35.39 | 500 | 17,695 | 2,973,716 | Form |
| 147 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 11132025 | 35.10 | 18,932 | 664,513 | 432,537 | Form |
| 148 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 11062025 | 31.85 | 2,678 | 85,297 | 1,707,691 | Form |
| 149 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 11062025 | 30.44 | 6,695 | 203,782 | 1,713,442 | Form |
| 150 | Oelschlager, Kristen M | Chief Operating Officer | Direct | Sell | 11042025 | 25.04 | 12,678 | 317,457 | 690,328 | Form |
| 151 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 10232025 | 22.44 | 1,339 | 30,047 | 1,413,451 | Form |
| 152 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 10062025 | 22.58 | 1,339 | 30,235 | 1,452,504 | Form |
| 153 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 9192025 | 21.97 | 1,339 | 29,419 | 1,442,748 | Form |
| 154 | Maetzold, Derek J | Pres. & Chief Exec. Officer | Direct | Sell | 9042025 | 23.93 | 1,339 | 32,042 | 1,603,430 | Form |
Castle Biosciences — Investor Video Playlist
Leadership
#FollowTheLeader with Frank Stokes: #CastleCulture
Products & Services
MyPath Test Prevents Overdiagnosis of Melanoma | Dr. Etan Marks Case Study
Products & Services
Atypical Skin Lesion in 54-Year-Old: How MyPath Melanoma Guided Surgical Decision | Dr. Brent Moody
Products & Services
DecisionDx-Melanoma Overview
Products & Services
Interview with Dr. Daniel Tseng: The Power of Risk Stratification for Barrett's Esophagus
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/12/2026